 |
|
Leukotriene Modifier Use and Asthma Severity
How Is a New Medication Being Used by Adults With Asthma?
Laurie Snyder, MD;
Paul D. Blanc, MD, MSPH;
Patricia P. Katz, PhD;
Edward H. Yelin, PhD;
Mark D. Eisner, MD, MPH
Arch Intern Med. 2004;164:617-622.
Background The introduction of leukotriene modifiers, the first novel class of medications for asthma in more than 2 decades, provided an opportunity to evaluate the clinical context in which patients receive new treatments. Because milder asthma is usually controllable with more familiar medications, we hypothesized that adults with asthma would receive leukotriene modifiers for more severe disease.
Methods We conducted a prospective, longitudinal, 18-month cohort study of 349 patients with asthma. We evaluated the association of baseline self-reported medication use and measures of asthma severity. We also examined the impact of baseline measurement of asthma severity on incident leukotriene modifier use at follow-up.
Results At baseline, 39 (11%) of 349 patients reported leukotriene modifier use during the previous 2 weeks (95% confidence interval [CI], 8%-15%). Adults with asthma who reported recent use of leukotriene modifiers were more likely to indicate use of other long-term controller medications for asthma, such as inhaled corticosteroids (80% vs 57%;P = .007). Leukotriene modifier use was also associated with poorer severity-of-asthma scores (mean score difference, 3.6 points; 95% CI, 1.7-5.2 points) and asthma-specific health-related quality of life (mean score difference, 8.1 points; 95% CI, 3.4-12.8 points). Leukotriene modifier users were also more likely to indicate a recent emergency department visit (odds ratio [OR], 2.3; 95% CI, 0.9-5.6) or hospitalization for asthma (OR, 4.1; 95% CI, 1.4-11.4). Greater baseline asthma severity was associated with an increased probability of new-onset leukotriene modifier use during 18-month follow-up. Poorer baseline severity-of-asthma scores and asthma-specific quality-of-life scores were related to a greater likelihood of leukotriene modifier use at follow-up (OR per SD-sized score increment, 2.0; 95% CI, 1.4-2.7; OR, 1.8; 95% CI, 1.3-2.5; respectively). Recent hospitalization for asthma at baseline was also associated with a greater likelihood of leukotriene modifier use at follow-up (OR, 4.9; 95% CI, 1.6-14.8).
Conclusions Adults with asthma who receive leukotriene modifiers have more severe asthma.
From the Department of Medicine (Drs Snyder, Blanc, and Eisner), Divisions of Occupational and Environmental Medicine and Pulmonary and Critical Care Medicine (Drs Blanc and Eisner), and Institute for Health Policy Studies (Drs Katz and Yelin), University of California, San Francisco. The authors have no relevant financial interest in this article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Area-level socio-economic status and health status among adults with asthma and rhinitis
Blanc et al.
Eur Respir J 2006;27:85-94.
ABSTRACT
| FULL TEXT
|
